SGLT2 in CKD
Beyond ACEis and ARBs: The Promise of SGLT2 Inhibition to Reduce Risk of Kidney Failure and Dialysis in Numerous Patient Populations
Speakers: Ramy Hanna, MD, FASN, FACP, FNKF, Assistant Clinical Professor, Medicine and NephrologyMeg Jardine, MD, PhD, FRACP, DirectorSilvio Inzucchi, MD, Professor of Medicine, Endocrinology
Duration: 60 minutes
Presented on: December 5, 2022
Ramy Hanna, MD, FASN, FACP, FNKF
Ramy Hanna, MD, FASN, FACP, FNKF
Assistant Clinical Professor, Medicine and NephrologyRamy Hanna, MD, FASN, FACP, FNKF, is an Associate Clinical Professor of Medicine and Nephrology at the University of California Irvine (UCI-Health). He is a clinician-educator working on reporting of anti vegf agent toxicity (systemic, and intravitreal). Dr. Hanna is interested in AHUS and TMA treatment and clinical outcomes as well as cases of C3 GN and novel outcomes with C5 and C3 complement blockade. He has done prior work on dysnatremias and sodium correction modeling, as well as optimization of vaptan clinical response. Dr. Hanna is looking to grow in EMR optimization and automation. He has specific interests within the expansive field of Artificial Intelligence/Machine Learning related to diagnostic algorithms to assist with TMA diagnoses.
Meg Jardine, MD, PhD, FRACP
Meg Jardine, MD, PhD, FRACP
DirectorMeg Jardine, MD, PhD, FRACP, is the Director of the NHMRC Clinical Trials Centre and Kidney Health Research Director. Her interests include the integration of clinical care and research endeavors and the promotion of learning health system principles to contribute to the efficient delivery. Professor Jardine has experience in the design and conduct of national and international trials and is particularly interested in response-adaptive techniques as a solution to many of the challenges facing trials in kidney disease. She contributes to policy setting and implementation as Board Member of the Kidney Health Initiative and is an executive committee member of the international nephrology guidelines body, KDIGO. Additionally, she is a nephrologist at Concord Repatriation General Hospital.
Silvio Inzucchi, MD
Silvio Inzucchi, MD
Professor of Medicine, EndocrinologySilvio Inzucchi, MD, is a Professor of Medicine at the Yale School of Medicine, where he serves as Clinical Chief of the Section of Endocrinology, Medical Director of the Yale Diabetes Center, and Program Director of the Endocrinology & Metabolism Fellowship. His research interests include pharmacological antihyperglycemic therapy in inpatient and outpatient settings; and the link between type 2 diabetes, insulin resistance, and cardiovascular complications. Dr. Inzucchi is well known as an author and lecturer in diabetes management for over two decades. He served as co-chair of the ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes and has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.
CME InformationBeyond ACEis and ARBs: The Promise of SGLT2 Inhibition to Reduce Risk of ESRD and Dialysis in Numerous Patient PopulationsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Kidney Disease: Improving Global Outcomes (KDIGO).
ACKNOWLEDGEMENTThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.
DATE OF LIVE ACTIVITYThis activity was released on December 5, 2022 and is valid for 12 months. Requests for credit must be made no later than December 5, 2023.
TARGET AUDIENCEThe educational design of this activity addresses the needs of nephrologists, cardiologists, endocrinologists, internal medicine physicians, primary care physicians, nurse practitioners and physician assistants. Secondary audiences include clinical pharmacists, nurses, and other clinicians who care for patients who are at risk for CKD or at high risk of progression.
STATEMENT OF NEED/PROGRAM OVERVIEWRecently, SGLT2 inhibitors have been shown to slow the progression of chronic kidney disease (CKD), independent of whether the patient has diabetes. However, CKD is a silently progressive disease and most patients do not have their kidney function evaluated regularly, leaving many patients with CKD that is not recognized until it is in an advanced stage.
Join a panel of expert clinicians to explore strategies to recognize predisposing risk factors for CKD and improve the timeliness of referrals to specialists. Panelists will review the most recent data on SGLT2 inhibitors in advanced kidney disease and demonstrate how to apply that evidence in a variety of patient scenarios. Clinicians will learn about dosage and titration, use of SGLT2 inhibitors with RAS inhibition, and impacts on blood pressure, intraglomerular pressure, and hyperfiltration.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Develop strategies for multidisciplinary care team members to assess kidney function in high-risk people because of race/ethnicity and/or the presence of predisposing conditions
- Summarize the evidence supporting the impact of SGLT2 inhibitors on the progression of CKD, including conversion to end-stage renal disease (ESRD), in patients with advanced CKD independent of impacts on co-existing conditions
- Describe the mechanisms by which SGLT2 inhibitors slow down progression of CKD to ESRD, including impacts on blood pressure, intraglomerular pressure, and hyperfiltration
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Ramy M. Hanna, MD, FASN, FACP, FNKF
Associate Professor of Medicine – I
Fellowship Program Director
University of California, Irvine
Contracted Research: Alexion, Appelis, Otsuka, Remegen, Roche
Speakers’ Bureau: Alexion, Aurinia, AstraZeneca, GSK, Otsuka
Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Chief, Endocrinology
Medical Director, Yale Diabetes Center
Yale School of Medicine
Yale New Haven Hospital
Consulting Fee (e.g., Advisory Board): Abbott, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Esperion, Lexicon, Merck/Pfizer, Novo Nordisk, VTV Therapeutics
Honoraria: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Esperion, Lexicon, Merck/Pfizer, Novo Nordisk, VTV Therapeutics
Meg J. Jardine, MD, PhD, FRACP
University of Sydney
Consulting Fee (e.g., Advisory Board): Akebia, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook Therapeutics, CSL Behring, Janssen, Vifor
Contracted Research: Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, MSD
Honoraria: Amgen, AstraZeneca, Janssen, Merck, MSD, Roche, Vifor
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Jaimee Harris-Gold Nothing to disclose Terry Glauser Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Technical Support:For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive or CardioCareLive at 877-394-1306 or at Support@ClinicalSeriesLive.com or Support@CardioCareLive.com.